ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 223 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85 | -18.3% | 15,525 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $104 | +1.0% | 15,525 | +33.4% | 0.00% | 0.0% |
| Q1 2023 | $103 | -7.2% | 11,642 | -19.9% | 0.00% | 0.0% |
| Q4 2022 | $111 | -99.9% | 14,533 | +2.3% | 0.00% | 0.0% |
| Q3 2022 | $101,000 | -12.2% | 14,213 | +0.1% | 0.00% | 0.0% |
| Q2 2022 | $115,000 | -66.8% | 14,199 | -43.0% | 0.00% | -66.7% |
| Q1 2022 | $346,000 | -72.8% | 24,913 | -45.0% | 0.00% | -40.0% |
| Q4 2021 | $1,270,000 | +89.8% | 45,256 | +129.9% | 0.01% | -16.7% |
| Q3 2021 | $669,000 | -21.7% | 19,684 | -5.8% | 0.01% | -14.3% |
| Q2 2021 | $854,000 | +49.6% | 20,896 | +47.4% | 0.01% | -66.7% |
| Q1 2021 | $571,000 | -37.4% | 14,180 | -8.0% | 0.02% | -40.0% |
| Q4 2020 | $912,000 | +21.6% | 15,418 | -0.0% | 0.04% | +6.1% |
| Q3 2020 | $750,000 | +5.0% | 15,424 | +4.5% | 0.03% | 0.0% |
| Q2 2020 | $714,000 | +57.6% | 14,753 | -9.6% | 0.03% | +200.0% |
| Q1 2020 | $453,000 | – | 16,311 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |